# A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

> **NCT01680991** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 48 (actual)

## Conditions studied

- Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma

## Interventions

- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT01680991
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2016-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01680991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01680991, "A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01680991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*